catalog number :
MBS730762
products type :
ELISA Kit
products full name :
Human Alpha Synuclein oligomer ELISA Kit
products short name :
Alpha Synuclein oligomer
other names :
Alpha-synuclein; Alpha-synuclein; alpha-synuclein; synuclein alpha-140; non A-beta component of AD amyloid; synuclein, alpha (non A4 component of amyloid precursor); Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP
products gene name :
AlphaSYNo
other gene names :
SNCA; SNCA; PD1; NACP; PARK1; PARK4; NACP; PARK1; NACP
uniprot entry name :
SYUA_HUMAN
specificity :
This assay has high sensitivity and excellent specificity for detection of SNCOalpha. No significant cross-reactivity or interference between SNCOalpha and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between SNCOalpha and all the analogues, therefore, cross reaction may still exist in some cases.
storage stability :
Store all reagents at 2-8 degree C.
other info1 :
Samples: Serum, plasma, cell culture supernatants, body fluid and tissue homogenate. Assay Type: Quantitative Competitive or Sandwich. Sensitivity: 1.0 pg/mL.
products categories :
Neurobiology
products description :
Intended Uses: This SNCOalpha ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Human SNCOalpha. This ELISA kit for research use only, not for therapeutic or diagnostic applications!. Principle of the Assay: SNCOalpha ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-SNCOalpha antibody and an SNCOalpha-HRP conjugate. The assay sample and buffer are incubated together with SNCOalpha-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the SNCOalpha concentration since SNCOalpha from samples and SNCOalpha-HRP conjugate compete for the anti-SNCOalpha antibody binding site. Since the number of sites is limited, as more sites are occupied by SNCOalpha from the sample, fewer sites are left to bind SNCOalpha-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The SNCOalpha concentration in each sample is interpolated from this standard curve.
ncbi mol weight :
13,109 Da
ncbi pathways :
Alpha-synuclein Signaling Pathway (137913); Alzheimer's Disease Pathway (83097); Alzheimer's Disease Pathway (509); Alzheimers Disease Pathway (672448); Amyloids Pathway (366238); Disease Pathway (530764); EGFR1 Signaling Pathway (198782); Parkin-Ubiquitin Proteasomal System Pathway (700638); Parkinson's Disease Pathway (83098); Parkinsons Disease Pathway (705377)
ncbi summary :
Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Four alternatively spliced transcripts encoding two different isoforms have been identified for this gene. [provided by RefSeq, Mar 2009]
uniprot summary :
SNCA: a member of the synuclein family. Abundantly expressed in the brain. Inhibits phospholipase D2 selectively. May integrate presynaptic signaling and membrane trafficking. Implicated in the pathogenesis of Parkinson s disease. A major component of amyloid plaques in the brains of patients with Alzheimer s disease. Two alternatively spliced isoforms transcripts have been identified. Protein type: Adaptor/scaffold. Chromosomal Location of Human Ortholog: 4q21. Cellular Component: Golgi apparatus; nuclear outer membrane; rough endoplasmic reticulum; mitochondrion; lysosome; fibril; extracellular region; terminal button; cell cortex; inclusion body; mitochondrial respiratory chain complex I; cytosol; actin cytoskeleton; platelet alpha granule membrane; synaptic vesicle; growth cone; axon; perinuclear region of cytoplasm; cytoplasm; plasma membrane; ribosome; nucleus; cell junction. Molecular Function: identical protein binding; protein domain specific binding; histone binding; zinc ion binding; kinesin binding; ferrous iron binding; microtubule binding; caspase inhibitor activity; beta-tubulin binding; magnesium ion binding; protein N-terminus binding; phosphoprotein binding; Hsp70 protein binding; oxidoreductase activity; calcium ion binding; dynein binding; protein binding; phospholipase binding; copper ion binding; phospholipid binding; tau protein binding; fatty acid binding; alpha-tubulin binding. Biological Process: regulation of long-term neuronal synaptic plasticity; negative regulation of serotonin uptake; regulation of acyl-CoA biosynthetic process; positive regulation of apoptosis; adult locomotory behavior; mitochondrial membrane organization and biogenesis; negative regulation of norepinephrine uptake; microglial cell activation; positive regulation of endocytosis; response to lipopolysaccharide; negative regulation of caspase activity; negative regulation of monooxygenase activity; dopamine biosynthetic process; negative regulation of transcription from RNA polymerase II promoter; fatty acid metabolic process; regulation of dopamine secretion; positive regulation of neurotransmitter secretion; negative regulation of dopamine uptake; negative regulation of histone acetylation; calcium ion homeostasis; response to magnesium ion; negative regulation of exocytosis; negative regulation of protein amino acid phosphorylation; behavioral response to cocaine; receptor internalization; phospholipid metabolic process; synapse organization and biogenesis; fibril organization and biogenesis; dopamine uptake; response to iron(II) ion; negative regulation of neuron apoptosis; positive regulation of receptor recycling; aging; response to drug; caspase activation; neutral lipid metabolic process; protein destabilization; regulation of glutamate secretion; regulation of macrophage activation; negative regulation of microtubule polymerization; positive regulation of peptidyl-serine phosphorylation; negative regulation of dopamine metabolic process; organelle ATP synthesis coupled electron transport; regulation of locomotion; synaptic vesicle endocytosis; positive regulation of release of sequestered calcium ion into cytosol; regulation of excitatory postsynaptic membrane potential; negative regulation of transporter activity; negative regulation of apoptosis. Disease: Parkinson Disease 4, Autosomal Dominant; Dementia, Lewy Body; Parkinson Disease 1, Autosomal Dominant
size1 :
48-Strip-Wells-(Competitive)
size2 :
48-Strip-Wells-(Sandwich)
size3 :
96-Strip-Wells-(Competitive)
size4 :
96-Strip-Wells-(Sandwich)